Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01877655


Additional trial details provided through ANZCTR are available at the end of this record.


Registration number
NCT01877655
Ethics application status
Date submitted
12/06/2013
Date registered
14/06/2013
Date last updated
24/10/2024

Titles & IDs
Public title
A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Secondary ID [1] 0 0
2013-000903-18
Secondary ID [2] 0 0
0113-CL-1004
Universal Trial Number (UTN)
Trial acronym
HELIOS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cytomegalovirus (CMV)-Positive Recipients 0 0
Allogeneic, Hematopoietic Cell Transplant (HCT) 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - ASP0113
Treatment: Drugs - Placebo

Experimental: ASP0113 - Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).

Placebo comparator: Placebo - Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).


Treatment: Other: ASP0113
Intramuscular injection

Treatment: Drugs: Placebo
Intramuscular injection
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Composite of All-Cause Mortality and Adjudicated Cytomegalovirus End Organ Disease (CMV EOD) Through 1 Year Post Transplant
Timepoint [1] 0 0
From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)
Secondary outcome [1] 0 0
Percentage of Participants With Protocol-Defined CMV Viremia Through 1 Year Posttransplant
Timepoint [1] 0 0
From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)
Secondary outcome [2] 0 0
Percentage of Participants With Adjudicated CMV-Specific Antiviral Therapy (AVT) Through 1 Year Posttransplant
Timepoint [2] 0 0
From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)
Secondary outcome [3] 0 0
Percentage of Participants With a Composite Endpoint of Protocol-defined CMV Viremia and Adjudicated CMV-Specific AVT Use
Timepoint [3] 0 0
From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)
Secondary outcome [4] 0 0
Percentage of Participants With First Occurrence of Adjudicated CMV-specific AVT or Adjudicated Diagnosis of CMV EOD After Study Drug First Injection Through 1 Year Posttransplant
Timepoint [4] 0 0
From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)
Secondary outcome [5] 0 0
All-Cause Mortality at 1 Year Posttransplant
Timepoint [5] 0 0
From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)

Eligibility
Key inclusion criteria
* Participant is a CMV-seropositive HCT recipient
* Participant is planned to undergo either of the following:

* Sibling Donor Transplant
* Unrelated Donor Transplant
* Participant has one of the following underlying diseases:

* Acute myeloid leukemia (AML)
* Acute lymphoblastic leukemia (ALL)
* Acute undifferentiated leukemia (AUL)
* Acute biphenotypic leukemia
* Chronic myelogenous leukemia (CML)
* Chronic lymphocytic leukemia (CLL).
* A defined myelodysplastic syndrome(s) (MDS)
* Primary or secondary myelofibrosis
* Lymphoma (including Hodgkin's)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participant has active CMV disease or infection or has received treatment for active CMV disease or infection within 3 months (90 days) prior to transplant
* Participant has a modified hematopoietic cell transplant comorbidity index (HCT-CI) score = 4
* Participant has received a prior HCT and has residual Chronic Graft-versus-host Disease (cGVHD)
* Participant who is scheduled to have a cord blood transplant or a haploidentical transplant
* Participant has a platelet count of less than 50,000 mm3 within 3 days prior to randomization (platelet transfusions are allowed)
* Participant has aplastic anemia or multiple myeloma

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/09/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2022
Sample size
Target
Accrual to date
Final
514
Recruitment in Australia
Recruitment state(s)
QLD,SA
Recruitment hospital [1] 0 0
Site AU43001 - Herston
Recruitment hospital [2] 0 0
Site AU43004 - Adelaide
Recruitment postcode(s) [1] 0 0
QLD 4029 - Herston
Recruitment postcode(s) [2] 0 0
SA 5000 - Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Tennessee
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Utah
Country [20] 0 0
United States of America
State/province [20] 0 0
Virginia
Country [21] 0 0
United States of America
State/province [21] 0 0
Washington
Country [22] 0 0
United States of America
State/province [22] 0 0
Wisconsin
Country [23] 0 0
Belgium
State/province [23] 0 0
Brugge
Country [24] 0 0
Belgium
State/province [24] 0 0
Leuven
Country [25] 0 0
Belgium
State/province [25] 0 0
Roeselare
Country [26] 0 0
Canada
State/province [26] 0 0
British Columbia
Country [27] 0 0
Canada
State/province [27] 0 0
Ontario
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
France
State/province [29] 0 0
Besancon
Country [30] 0 0
France
State/province [30] 0 0
Creteil
Country [31] 0 0
France
State/province [31] 0 0
Nantes
Country [32] 0 0
France
State/province [32] 0 0
Nice
Country [33] 0 0
Germany
State/province [33] 0 0
Bonn
Country [34] 0 0
Germany
State/province [34] 0 0
Dusseldorf
Country [35] 0 0
Germany
State/province [35] 0 0
Gottingen
Country [36] 0 0
Germany
State/province [36] 0 0
Koln
Country [37] 0 0
Germany
State/province [37] 0 0
Leipzig
Country [38] 0 0
Germany
State/province [38] 0 0
Mainz
Country [39] 0 0
Germany
State/province [39] 0 0
Muenster
Country [40] 0 0
Germany
State/province [40] 0 0
Stuttgart
Country [41] 0 0
Germany
State/province [41] 0 0
Tuebingen
Country [42] 0 0
Germany
State/province [42] 0 0
Ulm
Country [43] 0 0
Germany
State/province [43] 0 0
Wurzburg
Country [44] 0 0
Japan
State/province [44] 0 0
Aichi
Country [45] 0 0
Japan
State/province [45] 0 0
Gunma
Country [46] 0 0
Japan
State/province [46] 0 0
Hokkaido
Country [47] 0 0
Japan
State/province [47] 0 0
Tokyo
Country [48] 0 0
Japan
State/province [48] 0 0
Fukuoka
Country [49] 0 0
Japan
State/province [49] 0 0
Osaka
Country [50] 0 0
Korea, Republic of
State/province [50] 0 0
Seoul Teugbyeolsi
Country [51] 0 0
Korea, Republic of
State/province [51] 0 0
Seoul
Country [52] 0 0
Spain
State/province [52] 0 0
Badalona
Country [53] 0 0
Spain
State/province [53] 0 0
Barcelona
Country [54] 0 0
Spain
State/province [54] 0 0
Cordoba
Country [55] 0 0
Spain
State/province [55] 0 0
Granada
Country [56] 0 0
Spain
State/province [56] 0 0
Madrid
Country [57] 0 0
Spain
State/province [57] 0 0
Murcia
Country [58] 0 0
Spain
State/province [58] 0 0
Salamanca
Country [59] 0 0
Spain
State/province [59] 0 0
Santander
Country [60] 0 0
Spain
State/province [60] 0 0
Valencia
Country [61] 0 0
Sweden
State/province [61] 0 0
Gothenburg
Country [62] 0 0
Sweden
State/province [62] 0 0
Linkoping
Country [63] 0 0
Sweden
State/province [63] 0 0
Lund
Country [64] 0 0
Sweden
State/province [64] 0 0
Stockholm
Country [65] 0 0
Sweden
State/province [65] 0 0
Umea
Country [66] 0 0
Taiwan
State/province [66] 0 0
Taipei City
Country [67] 0 0
Taiwan
State/province [67] 0 0
Taoyuan County

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Astellas Pharma Global Development, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study was to evaluate the efficacy of ASP0113 compared with placebo as measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD) through 1 year post-transplant. Safety of ASP0113 in participants undergoing allogeneic HCT will also be evaluated.
Trial website
https://clinicaltrials.gov/study/NCT01877655
Trial related presentations / publications
Ljungman P, Bermudez A, Logan AC, Kharfan-Dabaja MA, Chevallier P, Martino R, Wulf G, Selleslag D, Kakihana K, Langston A, Lee DG, Solano C, Okamoto S, Smith LR, Boeckh M, Wingard JR, Cywin B, Fredericks C, Lademacher C, Wang X, Young J, Maertens J. A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. EClinicalMedicine. 2021 Mar 19;33:100787. doi: 10.1016/j.eclinm.2021.100787. eCollection 2021 Mar.
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Astellas Pharma Global Development, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01877655

Additional trial details provided through ANZCTR
Accrual to date
Recruitment state(s)
Funding & Sponsors
Primary sponsor
Primary sponsor name
Primary sponsor address
Primary sponsor country
Ethics approval
Ethics application status
 
Public notes
Please refer to ClinicalTrials.gov website link (https://clinicaltrials.gov/ct2/show/results/NCT01877655?term=0113-cl-1004&draw=2&rank=1) and EU CTR website link (https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000903-18/results) for results for this study.

Contacts
Principal investigator
Title 357 0
Name 357 0
Address 357 0
Country 357 0
Phone 357 0
Fax 357 0
Email 357 0
Contact person for public queries
Title 358 0
Name 358 0
Address 358 0
Country 358 0
Phone 358 0
Fax 358 0
Email 358 0
Contact person for scientific queries
Title 359 0
Name 359 0
Address 359 0
Country 359 0
Phone 359 0
Fax 359 0
Email 359 0